This is a tobacco budworm (Heliothis virescens). Toxins from Bacillus thuringiensis bacteria (Bt toxins) are used in organic and conventional farming to manage pest insects. Sprayed as pesticides or produced in genetically modified plants, Bt toxins, used in pest control since 1938, minimize herbivory in crops, such as vegetables, maize or cotton. Since 1996, Bt producing transgenic crops have been grown, which successfully control pests like the European corn borer, the tobacco budworm, the Western corn rootworm, and the cotton bollworm. Over the years, Bt resistant insects have emerged in organic and conventional farming. Scientists have therefore modified the molecular structure of two Bt toxins, Cry1Ab and Cry1Ac, in order to overcome resistance. The novel toxins, Cry1AbMod and Cry1AcMod, are effective against five resistant insect species, such as the diamondback moth, the cotton bollworm, and the European corn borer. Cry1AbMod and Cry1AcMod can be used alone or in combination with other Bt toxins for plant protection.

A new treatment for the deadly Hendra virus has proven successful in primate tests — a major step forward in combating the virus, which kills about 60 percent of those it infects and has been implicated in sporadic outbreaks in Australia ever since it was first identified in 1994.

Chronic fatigue syndrome (CFS) may be alleviated by the anti-cancer drug Rituximab, suggesting that the source of the disease could lie in the immune system, according to a new study published Oct. 19 in the online journal PLoS ONE. Uncertainty about the cause of CFS, which is characterized by extreme, unexplained exhaustion, among other symptoms, has led to much debate, but the authors of this recent study believe they may have found the answer.

Timing is everything when treating patients with both HIV and tuberculosis. Starting HIV therapy in such patients within two weeks of TB treatment, rather than two months as is the current practice, increases survival by 33 percent, according to a large-scale clinical trial in Cambodia led by researchers at Children's Hospital Boston and the Immune Disease Institute (IDI).